List of Excipients in Branded Drug ORILISSA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AbbVie Inc	ORILISSA	elagolix	0074-0038	CARMINIC ACID	2039-07-23
AbbVie Inc	ORILISSA	elagolix	0074-0038	MAGNESIUM STEARATE	2039-07-23
AbbVie Inc	ORILISSA	elagolix	0074-0038	MANNITOL	2039-07-23

Orilissa Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Orilissa, AbbVie’s elagolix product for endometriosis-associated pain, uses a conventional immediate-release oral tablet platform. Its commercial value is driven primarily by elagolix pharmacology, dose flexibility, and restricted treatment duration rather than differentiated excipient technology. The largest excipient opportunities are generic substitution, lactose-free reformulation, improved tablet manufacturability, patient-centric packaging, and combination or lifecycle products that preserve elagolix exposure while reducing tolerability and adherence barriers.

What is Orilissa and how is it regulated?

Orilissa contains elagolix sodium, a nonpeptide gonadotropin-releasing hormone antagonist. The FDA approved Orilissa in July 2018 for the management of moderate to severe pain associated with endometriosis in premenopausal women.[1]

Attribute	Orilissa
Active ingredient	Elagolix sodium
Dosage form	Immediate-release oral tablet
Strengths	150 mg and 200 mg
150 mg regimen	Once daily
200 mg regimen	Twice daily
Primary indication	Endometriosis-associated pain
Manufacturer	AbbVie
FDA approval	July 23, 2018
Small-molecule pathway	NDA
Generic pathway	ANDA, subject to applicable patents and exclusivities
Biosimilar pathway	Not applicable

The two dose strengths support different efficacy and tolerability profiles. The 150 mg once-daily regimen is generally used for longer treatment periods, while the 200 mg twice-daily regimen is used when coexisting dyspareunia requires greater suppression, subject to a shorter recommended treatment duration because of bone mineral density concerns.[1]

Orilissa is not a biologic. Biosimilar competition is therefore not relevant. Competitive entry would normally occur through an abbreviated new drug application for an elagolix tablet that demonstrates pharmaceutical equivalence, bioequivalence, and compliance with applicable patent certifications.

What excipients are used in Orilissa tablets?

Orilissa uses standard tablet excipients rather than a proprietary controlled-release or lipid-based delivery system. The FDA prescribing information identifies inactive ingredients in the tablet core and film coating, including lactose monohydrate, povidone, crospovidone, magnesium stearate, polyvinyl alcohol, titanium dioxide, talc, polyethylene glycol, and iron oxide colorants.[1]

The formulation can be understood as four functional excipient groups:

Excipient function	Representative materials	Commercial purpose
Dilution and bulk	Lactose monohydrate	Provides tablet mass and supports direct-compression or granulation performance
Binding	Povidone	Improves compactability and mechanical strength
Disintegration	Crospovidone	Promotes rapid tablet breakup and immediate release
Lubrication	Magnesium stearate	Reduces tooling friction and ejection force
Film coating	Polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide	Protects the tablet, improves appearance, and supports handling
Color	Iron oxide pigments	Differentiates strengths and supports product identification

The formulation strategy is commercially efficient. Lactose and crospovidone are widely available, the tablet is immediate release, and the film coating is conventional. These characteristics reduce manufacturing complexity but also make excipient differentiation difficult for a generic competitor to claim.

How does Orilissa’s excipient design affect generic development?

The principal generic challenge is not excipient novelty. It is matching elagolix exposure across a low-dose, potent active pharmaceutical ingredient with two marketed strengths and different dosing regimens.

A generic developer would typically prioritize:

1. Matching the reference product’s dissolution profile across relevant pH conditions.
2. Controlling content uniformity at the active ingredient level.
3. Demonstrating bioequivalence for the marketed strengths or using a strength-waiver strategy where permitted.
4. Preserving tablet hardness, friability, disintegration, and coating performance.
5. Avoiding excipients that alter gastrointestinal permeability, transit, or elagolix metabolism.
6. Managing color and imprint differences without creating medication-error risk.

Crospovidone and magnesium stearate require particular process control. Excessive magnesium stearate mixing can reduce wettability and slow dissolution. Excessive compression force can delay disintegration, especially where a high tablet-hardness target is used. Lactose particle size, moisture, and supplier grade can affect blend uniformity and compression behavior.

Because elagolix is administered at a low dose relative to the tablet mass, blend uniformity and segregation control are central manufacturing issues. A developer that replaces lactose with mannitol, microcrystalline cellulose, or a co-processed excipient would need to demonstrate that the substitution does not change dissolution, stability, or bioequivalence.

What formulation patents protect Orilissa?

The commercially relevant intellectual property is expected to center on elagolix composition-of-matter rights, pharmaceutical compositions, therapeutic uses, dosing regimens, and related formulation claims. The excipient list itself is unlikely to provide meaningful standalone exclusivity because the named ingredients are common pharmaceutical materials.

For generic-entry analysis, the relevant sources are:

• FDA Orange Book patent listings for the Orilissa NDA.
• FDA-approved product labeling.
• USPTO prosecution records for elagolix patents.
• ANDA Paragraph IV notices and related Hatch-Waxman litigation records.
• Court dockets involving AbbVie and generic applicants.

Orilissa patent coverage should be separated into four categories:

Patent category	Relevance to commercial entry
Composition of matter	Usually the strongest barrier; may cover elagolix or a salt, polymorph, or chemical genus
Pharmaceutical composition	May cover elagolix with defined excipient classes, ratios, or dissolution properties
Method of use	May cover treatment of endometriosis, uterine disorders, dosing schedules, or symptom control
Manufacturing process	Can create process-specific barriers but is less likely to block all tablet manufacture

An excipient substitution generally does not avoid a composition-of-matter patent covering elagolix. It may, however, avoid a narrow formulation claim that requires particular excipient ratios, particle properties, release characteristics, or manufacturing steps.

When does Orilissa lose exclusivity?

FDA market exclusivity and patent expiry are separate issues. Orilissa’s FDA approval in 2018 does not establish the end of patent protection. Generic entry depends on the latest enforceable patent, pediatric exclusivity, regulatory exclusivity, litigation outcomes, and any settlement terms.

Exclusivity issue	Commercial effect
New chemical entity exclusivity	Delayed ANDA approval for the statutory period after approval
Orange Book-listed patents	May delay approval or trigger Paragraph IV litigation
Pediatric exclusivity	Can extend relevant listed-patent protection by six months
Method-of-use patents	May permit a skinny-label generic if protected uses can be carved out
Composition patents	Can block broad generic entry until expiration or invalidation
Settlement agreements	May establish an earlier authorized or licensed generic entry date

Elagolix is a small molecule, so the competitive path is not governed by biosimilar interchangeability rules. The most important event for investors and manufacturers is the first credible ANDA challenge combined with the Orange Book patent profile.

Which companies are challenging Orilissa with generics?

A definitive list of challengers requires current FDA and federal court records. Public commercial analysis should distinguish between:

• An ANDA filing without a Paragraph IV certification.
• A Paragraph IV certification alleging patent invalidity, unenforceability, or non-infringement.
• A notice-letter dispute that has not resulted in litigation.
• A filed Hatch-Waxman action.
• A settlement or license that provides an agreed launch date.

A generic company’s excipient strategy becomes commercially relevant only after it has selected an entry pathway and confirmed that the formulation can meet bioequivalence requirements. Substitution of lactose, coating pigments, or disintegrants is unlikely to create a market advantage by itself unless it solves a meaningful patient or manufacturing problem.

What excipient opportunities exist for generic Orilissa?

Lactose-free and reduced-intolerance formulations

The reference product uses lactose monohydrate. A lactose-free generic could use mannitol, microcrystalline cellulose, dibasic calcium phosphate, or a co-processed filler system. The commercial opportunity is targeted rather than broad because lactose intolerance does not automatically imply intolerance to the small amount present in a tablet.

A lactose-free claim may still help:

• Hospital and health-system formulary positioning.
• Patient preference and pharmacy substitution.
• International markets with different excipient labeling expectations.
• Portfolio differentiation where several generic products are otherwise interchangeable.

The product would need to avoid implying a clinical benefit that has not been established.

Improved moisture and stability performance

Elagolix tablet stability may be improved through excipient selection, packaging, and coating control. Opportunities include:

• Lower-moisture filler systems.
• Desiccant-supported bottles.
• High-barrier blister packaging.
• Optimized film-coating weight.
• Reduced exposure to oxygen and humidity during manufacturing.

Packaging may deliver more practical value than a novel excipient because tablets are already immediate release and use established materials.

Patient-centric tablet design

Orilissa treatment involves daily or twice-daily administration, with treatment duration constrained by bone mineral density risk. Commercial opportunities include:

• Smaller tablets.
• Clear strength differentiation.
• Calendar blister packs.
• Monthly adherence packs.
• Packaging that separates 150 mg and 200 mg regimens.
• Improved tablet markings for pharmacy-level error prevention.

A smaller tablet could improve swallowing but may increase content-uniformity and compression challenges. A packaging-based lifecycle strategy may be easier to implement than a new dosage form.

Taste and swallowability

Orilissa is swallowed whole, so taste masking is not a primary product requirement. A smaller coated tablet or an orally disintegrating formulation could have value for patients with dysphagia, but such products would likely require a more extensive regulatory strategy than a conventional ANDA.

An orally disintegrating tablet could create a 505(b)(2) opportunity if it provides a clinically relevant administration benefit. The commercial case would depend on evidence of demand, reimbursement, and the ability to preserve elagolix pharmacokinetics.

Modified-release formulations

Modified release is a technically possible but commercially difficult opportunity. Orilissa’s marketed regimens depend on defined systemic exposure and dose-dependent suppression. A once-daily modified-release product based on the 200 mg regimen would require pharmacokinetic and clinical justification.

Potential benefits include:

• Reduced dosing frequency.
• Lower peak-related adverse effects.
• More consistent exposure.
• Improved adherence.

Potential barriers include new clinical studies, formulation patents, higher development cost, and uncertainty over payer willingness to reimburse a premium product.

What method-of-use opportunities are available for elagolix?

Elagolix has potential lifecycle opportunities beyond the existing endometriosis indication, but method-of-use rights can be narrower and more vulnerable to label carve-outs than composition patents.

Potential areas include:

• Endometriosis-associated pain.
• Uterine fibroids.
• Dose sequencing with add-back therapy.
• Patient subgroups defined by symptom severity or menopausal status.
• Combination regimens designed to mitigate hypoestrogenic effects.
• Treatment algorithms based on duration, bone mineral density, or prior hormonal therapy.

The commercial value of a method-of-use patent depends on whether the indication is central to prescribing. If a generic can omit the protected use from its label while retaining approval for an unprotected indication, the patent may not prevent all sales.

How does Orilissa compare with competing endometriosis treatments?

Orilissa competes with hormonal contraceptives, progestins, GnRH agonists, other GnRH antagonists, surgery, and nonhormonal analgesics. Its excipient platform is less differentiated than the therapeutic positioning.

Product category	Typical differentiation	Excipient opportunity
Elagolix tablets	Oral GnRH antagonism, dose flexibility	Generic substitution, adherence packaging, lactose-free version
GnRH agonists	Injectable or depot delivery	Device, depot matrix, administration convenience
Progestins	Established oral hormonal treatment	Low-cost tablets, tolerability, combination products
Combined hormonal products	Contraception plus symptom control	Packaging and formulation convenience
Nonhormonal analgesics	Symptom relief without ovarian suppression	Fixed-dose combinations and gastrointestinal tolerability

Elagolix’s principal commercial advantage is oral administration without injection logistics. Its principal limitations are duration restrictions, hypoestrogenic effects, bone mineral density concerns, and cost relative to older hormonal therapies.[1,2]

What is the commercial value of Orilissa’s excipient platform?

The direct value of the excipient platform is moderate to low. The major value resides in the active ingredient and clinical label.

Commercial opportunities can be ranked as follows:

Opportunity	Development complexity	Commercial potential
Conventional generic tablet	Moderate	High if patent barriers permit entry
Lactose-free generic	Moderate	Moderate niche value
Improved blister or adherence packaging	Low to moderate	Moderate
Smaller tablet	Moderate	Moderate
505(b)(2) orally disintegrating tablet	High	Uncertain
Modified-release tablet	High	Potentially high, but evidence-intensive
Combination product with add-back therapy	High	Potentially high
New excipient supplier relationship	Low	Limited unless it reduces cost or improves quality

Generic manufacturers should focus on cost of goods, dissolution robustness, supply continuity, and regulatory simplicity. A complex excipient system would increase development and manufacturing risk without necessarily improving substitutability.

Excipient suppliers may pursue value through preferred-grade positioning. Relevant selling points include tight particle-size distribution, low moisture, high compactability, low peroxide content, reduced magnesium stearate variability, and reliable global supply. These attributes can improve process capability but are unlikely to create product-level exclusivity.

What generic launch scenarios exist for Orilissa?

Early licensed entry

AbbVie could license or settle with a generic manufacturer, allowing entry before the last relevant patent expires. The agreement could provide for an authorized generic, a fixed launch date, or tiered entry by strength.

Post-patent broad entry

If composition and use patents expire without enforceable barriers, multiple ANDA holders could enter close together. Price erosion would likely be rapid because the product is an immediate-release tablet with standard excipients.

Skinny-label entry

A generic could omit a patented indication or dosing instruction if FDA labeling rules permit the carve-out. This approach would reduce infringement exposure but could limit pharmacy substitution or payer coverage.

Formulation-led 505(b)(2) entry

A company could pursue an improved dosage form, such as a modified-release or orally disintegrating tablet. This path would offer greater differentiation but require more regulatory evidence and may face new patent disputes.

What regulatory risks affect an Orilissa excipient program?

FDA review would focus on pharmaceutical equivalence, bioequivalence, dissolution, impurities, stability, and labeling. The key risks are:

• Uncontrolled low-dose blend uniformity.
• Dissolution differences caused by filler or lubricant substitution.
• Excipient-related degradation products.
• Tablet-strength differentiation failures.
• Packaging changes that reduce stability.
• Unsupported claims about lactose intolerance, tolerability, or adherence.
• Failure to match the reference product’s inactive-ingredient tolerances.
• New clinical exposure requirements for modified-release or alternative dosage forms.

FDA-approved excipient use does not eliminate formulation risk. The same excipient at a different grade, particle size, supplier, or concentration can produce different manufacturing and dissolution results.

Key Takeaways

• Orilissa is an immediate-release elagolix tablet with a conventional excipient system.
• The reference formulation uses lactose monohydrate, povidone, crospovidone, magnesium stearate, and standard film-coating materials.[1]
• The active ingredient and patent estate, not excipient novelty, are the primary barriers to generic entry.
• A lactose-free formulation is the clearest excipient-led differentiation opportunity.
• Packaging, tablet-size optimization, and strength differentiation may generate more commercial value than a novel excipient platform.
• Modified-release, orally disintegrating, and add-back combination products offer larger potential markets but require materially greater regulatory investment.
• Orilissa is a small molecule, so biosimilar competition does not apply.
• Generic developers should prioritize bioequivalence, dissolution robustness, content uniformity, and supply-chain cost.
• Excipient suppliers can compete through grade consistency, moisture control, compactability, and global supply reliability.
• Current Orange Book listings, Paragraph IV notices, litigation dockets, and settlement terms determine the practical timing of generic entry.

FAQs

Can a generic Orilissa use different excipients?

Yes. An ANDA applicant can use different inactive ingredients if the product remains pharmaceutically equivalent, meets FDA requirements, and demonstrates bioequivalence. The substitution cannot compromise dissolution, stability, content uniformity, or safety.

Is Orilissa suitable for a lactose-free reformulation?

Yes, from a formulation perspective. Lactose monohydrate could potentially be replaced with mannitol, microcrystalline cellulose, or another suitable filler. The replacement would require comparative development and regulatory support.

Could Orilissa be reformulated as an extended-release tablet?

Potentially, but the product would likely require a more demanding regulatory pathway than a conventional generic. Pharmacokinetic bridging and clinical justification would be important because altered exposure could affect efficacy and hypoestrogenic adverse effects.

Does Orilissa have biosimilar competition?

No. Elagolix is a chemically synthesized small molecule. Competition would proceed through the generic drug framework rather than the biosimilar pathway.

Which excipient is most important for Orilissa dissolution?

Crospovidone is a key disintegrant, while magnesium stearate level and mixing time can materially affect wetting and dissolution. Filler grade, compression force, and coating weight also influence the final dissolution profile.

References

1. U.S. Food and Drug Administration. (2024). Orilissa (elagolix) prescribing information. AbbVie Inc.
2. Taylor, H. S., Giudice, L. C., Lessey, B. A., et al. (2017). Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. New England Journal of Medicine, 377(1), 28-40.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. AbbVie Inc. (2024). Annual report and Form 10-K.
5. U.S. Food and Drug Administration. (2024). Inactive ingredient database.